IMPORTANCE Synaptic loss is an early pathologic substrate of Alzheimer disease (AD). Neurogranin is a postsynaptic neuronal protein that has demonstrated utility as a cerebrospinal fluid (CSF) marker of synaptic loss in AD.
Neuronal and synaptic loss reflects the cumulative outcome of different pathologic substrates in AD and, therefore, may provide the best surrogate for clinical and radiologic disease progression. 2, [4] [5] [6] [7] Synaptic dysfunction is an early and prominent pathologic feature of AD that precedes frank neuronal loss in several brain regions. [8] [9] [10] [11] [12] Cortical synaptic density is reduced by 25% to 30% and synaptic density per neuron by 15% to 35% in even the earliest symptomatic stages of the disease. 5, 7 Presynaptic, synaptic, and postsynaptic protein expression levels are reduced in postmortem AD brains compared with controls. 13, 14 Neurogranin is a calmodulin-binding postsynaptic 15 neuronal protein 16 that is abundantly expressed in perikaryal and dendritic cytoplasm. 15 Neurogranin is thought to be involved in activity-dependent synaptic plasticity and long-term potentiation through the modulation of calcium-mediated signaling pathways. [17] [18] [19] Because of its abundant and preferential neuronal expression, neurogranin has been identified as a potential marker of neurodegeneration in large-scale gene arrays, 20 along with other candidate markers, such as visininlike protein-1 (VILIP-1). [21] [22] [23] Previous studies suggest that cerebrospinal fluid (CSF) neurogranin levels are elevated in AD 24 and predict conversion from mild cognitive impairment (MCI) to AD dementia.
25-27
We investigate the diagnostic and prognostic utility of CSF neurogranin levels in a large cohort of well-characterized individuals with early AD and controls who were followed up for 2 to 3 years. Our results are consistent with previous reports 25, 26 of increased CSF neurogranin levels in AD. Furthermore, we found that CSF neurogranin levels correlate with wholebrain and regional atrophy in AD and with amyloid load in preclinical AD. Importantly, in our cohort, CSF neurogranin levels predicted rates of cognitive decline in patients with early symptomatic AD and future cognitive impairment in cognitively normal controls similarly to the CSF proteins VILIP-1, tau, and p-tau181 over time.
Methods

Participants
Participants were community-dwelling volunteers enrolled in longitudinal studies of healthy aging and dementia through the Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, from January 21, 2000, through March 21, 2011. Data analysis was performed from November 1, 2013, to March 31, 2015. All participants in this study were included in a previous study of CSF VILIP-1 in AD to allow comparison of markers (eMethods in the Supplement). 21, 22 Participants were in good general health with no other medical illness that could contribute to dementia and no contraindication to lumbar puncture (LP) or magnetic resonance imaging (MRI). APOE genotypes were obtained as previously described.
28
The Clinical Dementia Rating (CDR) was used to denote the presence or absence of symptomatic AD and, when present, its severity. 29, 30 A CDR score of 0, indicating no dementia, characterizes individuals who are cognitively normal. In the cohort being studied, a CDR score of 0. 
CSF Collection and Processing
The CSF samples (20-30 mL) were collected from all participants and analyzed for total tau, p-tau181, and Aβ 1-42 (Aβ42) by enzyme-linked immunosorbent assays (Innotest, Fujirebio [formerly Innogenetics]). 41 The CSF samples were analyzed for VILIP-1 by a microparticle-based immunoassay (Erenna, Singulex).
21,22
The CSF neurogranin levels were measured using a 2-site immunoassay that uses an affinity-efficient trapping and purification technique for polyclonal antibodies developed in the Laboratory of Jack H. Ladenson, PhD, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri (eMethods in the Supplement). Cox proportional hazards regression models tested the effects of CSF biomarkers, individually or in combination (using principal components analyses), on the conversion rate from a CDR score of 0 to a CDR score of 0.5 or higher (SAS Institute, Inc). The CSF biomarker measures were analyzed as continuous and categorical (dichotomized at the 85th percentile value) variables, adjusting for age, sex, educational level, and APOE ε4 genotype. The bootstrap method was used to compare CSF biomarkers (individually or in combination) as predictors of conversion in nonnested models 46,47 (R Project for Statistical Computing, R Foundation). Mixed linear models (PROC MIXED, SAS Institute Inc) tested the ability of CSF biomarkers to predict annual change in CDR-SB, global, episodic memory, semantic memory, working memory, or visual-spatial composite scores in AD over time (SAS statistical software, version 9.2). Analyses were adjusted for age, educational level, sex, APOE ε4 genotype, and baseline dementia severity (eMethods in the Supplement). Statistical significance was defined as P < .05 for all analyses. Of the 302 participants from the Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, included in this study, 221 participants (164 controls and 57 patients with AD) had more than 1 annual cognitive assessment during follow-up. For comparison, 19 research participants with a clinical diagnosis of frontotemporal lobar degeneration (n = 11), progressive supranuclear palsy (n = 7), or Lewy body dementia (n = 1) at the UCSF Memory and Aging Center were included in this study.
Results
Participants
The demographic, clinical, psychometric, genotype, and CSF biomarker characteristics of the study participants are summarized in the Table. Individuals with symptomatic AD were older than controls and included a higher percentage of individuals with the APOE ε4 genotype or with cortical amyloid binding on PET-PiB. Baseline Mini-Mental State Examination and psychometric composite scores were lower and baseline CDR-SB scores were higher in patients with AD than in controls. The CSF neurogranin levels did not differ by age or sex in this cohort (eResults in the Supplement).
Participants with very mild (CDR score of 0.5, n = 70), mild (CDR score of 1, n = 22), and moderate (CDR score of 2, n = 3) symptomatic AD exhibited the typical CSF biomarker phenotype of AD with higher mean levels of CSF tau, p-tau181, tau/ Aβ42, and p-tau181/Aβ42 and lower mean levels of CSF Aβ42 compared with controls ( Figure 1 and eFigure 1 in the Supplement). As previously reported in this cohort, mean CSF VILIP-1 and CSF VILIP-1/Aβ42 levels were higher in patients with AD than in controls. The CSF neurogranin levels predicted PiB status with comparable utility to that of the other CSF biomarkers, irrespective of clinical diagnoses ( Figure 1F ). The mean (SE) AUC was 0.86 (0.03) for tau, 0.81 (0.04) for p-tau181, 0.87 (0.03) for Aβ42, 0.77 (0.04) for VILIP-1, and 0.73 (0.04) for neurogranin. The mean (SE) AUCs for the CSF marker ratios to Aβ42 were 0.95 (0.02) for tau/Aβ42, 0.95 (0.02) for p-tau181/Aβ42, 0.93 (0.02) for VILIP-1/Aβ42, and 0.89 (0.03) for neurogranin/ Aβ42. The CSF neurogranin differentiated PiB-positive from PiB-negative individuals with a sensitivity of 79% and a specificity of 60%. The ratios of CSF tau, p-tau181, VILIP-1, and neurogranin to CSF Aβ42 levels provided higher diagnostic accuracy than each marker alone (respectively) and higher diagnostic accuracy for PiB status than for clinical diagnoses ( Figure 1 and eTable 1 in the Supplement).
Diagnostic Utility of CSF Neurogranin in AD
The CSF neurogranin levels correlated with CSF VILIP-1 (r = 0.76 and r = 0.83), tau (r = 0.81 and r = 0.77), and p-tau181 (r = 0.80 and r = 0.77) levels in patients with AD and controls, respectively (P < .001). No correlations were observed between CSF neurogranin levels and CSF Aβ42 levels in patients with AD (r = −0.03, P = .77) or controls (r = 0.12, P = .10) ( Figure 2 and eFigure 2 in the Supplement). The CSF neurogranin levels negatively correlated with baseline normalized whole-brain (r = −0.38, P = .02), hippocampal (r = −0.36, P = .03), entorhinal (r = −0.46, P = .006), and parahippocampal volumes (r = −0.47, P = .005) in AD (n = 38), adjusting for age, sex, and scanner type ( Figure 2 and eTable 2 in the Supplement). No correlations between the CSF neurogranin levels and brain volumes were observed in controls (n = 144) (eResults in the Supplement).
The CSF neurogranin levels correlated with MCBP on PET-PiB in the combined (r = 0.28, P < .001, n = 152) ( Figure 2 ) and control cohorts (r = 0.29, P = .001, n = 128) but not in the AD cohort (r = −0.1, P = .68, n = 24). The CSF neurogranin/Aβ42 levels correlated with MCBP in the AD (r = 0.54, P = .01) and control (r = 0.65, P < .001) cohorts. The CSF neurogranin levels correlated with MCBP (r = 0.39, P = .02) in PiB-positive, cognitively normal controls (ie, MCBP ≥0.18, n = 36) (Figure 2 ).
Ability of CSF Neurogranin Levels to Predict Future Cognitive Impairment in Controls
Cox proportional hazards regression models assessed the ability of CSF biomarkers (as continuous or categorical variables) to predict future cognitive impairment in cognitively normal controls over time (eTable 3 in the Supplement), adjusting for age, sex, educational level, and APOE ε4 genotype (eTable 4 in the Supplement and Figure 3 ). Analyses included cognitively normal controls who had at least 1 follow-up annual cognitive assessment (n=164). Of these, 26 participants (15.9%) progressed from CDR scores of 0 to a CDR score of 0.5 or higher during follow-up. With the exception of CSF Aβ42, all CSF biomarkers predicted conversion from a CDR score of 0 to a CDR score of 0.5 or higher during follow-up (eTable 4 in the Supplement). The CSF neurogranin (adjusted hazard ratio, 1.89; 95% CI, 1.29-2.78; P = .001) and neurogranin/Aβ42 (adjusted hazard ratio, 27.9; 95% CI, 6.93-112.1; P < .001) levels predicted conversion from a CDR score of 0 to a CDR score of 0.5 or higher over time. Individuals whose neurogranin or neurogranin/Aβ42 levels were in the upper 15th percentile of values progressed more rapidly to cognitive impairment than individuals whose levels were in the lower 85th percentile (Figure 3) .
Results from the bootstrap analyses indicate that the predictive ability for future cognitive impairment was 0.890 (P = .001) for neurogranin, 0.892 (P = .001) for VILIP-1, 0.866 (P = .002) for tau, 0.452 (P = .04) for p-tau181, 0.328 (P = .11) for Aβ42, 0.993 (P < .001) for neurogranin/Aβ42, 0.998 (P < .001) for VILIP-1/Aβ42, 0.974 (P < .001) for tau/Aβ42, and 0.902 (P = .002) for p-tau181/Aβ42. The combinations of CSF neurogranin and tau (0.885, P = .001) and of CSF neurogranin and p-tau181 (0.758, P = .007) were stronger predictors of conversion than tau (0.866, P = .002) or p-tau181 (0.452, P = .04) alone, respectively. When neurogranin was added to the combination of VILIP-1, tau, and p-tau181, the 4 markers together were stronger predictors of conversion (0.869, P = .002) than the combination of VILIP-1, tau, and p-tau181 (0.844, P = .002). When neurogranin was added to the combination of VILIP-1, tau, p-tau181, and Aβ42, the combination of all 5 markers (0.859, P = .002) was a stronger predictor of conversion than the combination of VILIP-1, tau, p-tau181, and Aβ42 (0.826, P = .002).
Ability of CSF Neurogranin Levels to Predict Rates of Cognitive Decline in AD
All CSF biomarkers except CSF Aβ42 predicted annual change in CDR-SB, global, episodic, and semantic memory scores in patients with symptomatic AD (n = 57) during follow-up (eTable 5 in the Supplement and Figure 4) . Baseline CSF neurogranin levels (as continuous measures) predicted annual change in CDR-SB (β estimate, 0.29, P = .001), global (β estimate, −0.11, P = .001), episodic memory (β estimate, −0.18, P < .001), and semantic memory (β estimate, −0.06, P = .04) scores. Baseline CSF neurogranin/Aβ42 levels predicted annual change in CDR-SB (β estimate, 0.27, P = .001), global (β estimate, −0.13, P < .001), episodic memory (β estimate, −0.16, P < .001), and semantic memory (β estimate, −0.06, P = .02) scores. Individuals with AD whose CSF neurogranin or neurogranin/Aβ42 levels were in the upper tercile (corresponding to a CSF neurogranin level pg/mL, n = 67) and those with CDR scores of 1 or higher (680 [57] pg/mL, n = 25) compared with those with CDR scores of 0 (296 [11] pg/mL, n = 197) (P < .001) and non-AD dementias (319 [48] pg/mL, n = 19) (P < .001). One-way analysis of variance with Welch correction for unequal variances and the Tukey post hoc test were used for all group comparisons. Similar results were obtained when Bonferroni corrections were used for all group comparisons. E and F, Receiver operating characteristic curves for the diagnostic utility of CSF biomarkers in differentiating AD from controls by clinical diagnosis and PiB status. 
Discussion
Neurogranin is a calmodulin-binding 16 postsynaptic neuronal protein 15 that is abundantly expressed in neuronal perikarya and dendritic spines. 15, 16 Studies suggest that neurogranin is involved in synaptic plasticity, synaptic regeneration, and long-term potentiation through the modulation of calcium-and calmodulin-signaling pathways [17] [18] [19] and plays an important role in memory and learning. 16, [48] [49] [50] [51] Neurogranin has been proposed as a potential marker of synaptic injury in large-scale gene arrays 20 because of its preferential neuronal expression and widespread distribution in different brain regions. 52 Pathologic studies 13, 14, 53 indicate that neurogranin immunoreactivity is reduced in patients with early symptomatic AD compared with controls. Because expression levels of other synaptic proteins are also decreased in AD 13, 14 and correlate with dementia severity, 6 ,53-55 reduced tissue neurogranin levels in AD are thought to reflect synaptic degeneration and loss of whole synaptic elements in the presence of AD. 13, 14 The extracellular release of synaptic elements as a result of ADassociated synaptic degeneration likely explains previous reports 25,26 of increased CSF neurogranin levels in AD.
We confirm the diagnostic utility of CSF neurogranin in a large, well-characterized cohort of AD and controls using a highly sensitive immunoassay developed in the Laboratory of Jack H. Ladenson, PhD, Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri. Furthermore, we found that CSF neurogranin levels correlate with brain atrophy in AD, with amyloid load in preclinical AD, and with other CSF markers of AD in patients with AD and controls. Importantly, we report for the first time, to our knowledge, that CSF neurogranin predicts future cognitive impairment in cognitively normal controls as well as the other CSF biomarkers and complements their predictive ability (collectively) for future cognitive impairment during a 2-to 3-year follow-up period.
In our cohort, the diagnostic utility of CSF neurogranin in differentiating patients with AD from controls was comparable to that of other CSF markers. Because most of our AD cohort includes individuals with very mild dementia (CDR score of 0.5), some of whom may elsewhere be classified as having MCI or pre-MCI, neurogranin may be a useful diagnostic marker for even the earliest symptomatic stages of the disease. The diagnostic accuracy of all CSF biomarkers and ratios was higher in relation to PiB status than in relation to clinical diagnoses, supporting the potential value of CSF biomarkers in identifying AD irrespective of clinical status. Synaptic loss or dysfunction is an early and primary pathologic substrate of AD. [8] [9] [10] [11] [12] Cognitive deficits attributed to synaptic dysfunction occur in the absence of, or even before, neuronal loss in AD. 55 Cortical synaptic density is reduced by as much as 35% in even the earliest stages of AD 56 and reflects neuronal loss and reduced synaptic density of viable neurons. 57 Synaptic loss is a good surrogate for cognitive decline and disease progression in AD 5,7,10,58 because it appears to be more closely correlated with cognitive deficits than the numbers of plaques or tangles or extent of cortical gliosis in pathologic studies 5, 7 of postmortem AD brains.
We found that baseline CSF neurogranin, VILIP-1, 21,22 tau, and p-tau181, [59] [60] [61] [62] but not CSF Aβ42, 61, 63, 64 levels predict future cognitive impairment in cognitively normal controls and rates of cognitive decline in patients with symptomatic AD over time.
Importantly, CSF neurogranin levels predicted future cognitive impairment in cognitively normal controls similarly to other CSF markers of AD in this cohort and complemented their collective predictive ability for future cognitive decline. These findings are consistent with previous reports [65] [66] [67] and proposed models of disease progression that suggest the presence of significant synaptic disease years before symptom onset. 63, 78 with rates of cognitive decline have previously been reported. Therefore, CSF markers of neuronal or synaptic loss or tau disease are more closely associated with future cognitive decline than CSF markers of amyloid disease during short follow-up periods. The CSF neurogranin levels correlate with brain atrophy in our AD cohort, with higher CSF neurogranin levels indicating Our study is limited by the short duration of follow-up. It will be important to validate these findings across different centers. Because synaptic dysfunction may occur in the absence of synaptic loss, 57 the identification of imaging markers of synaptic function may provide further insight into synaptic disease in AD and complement information provided by the CSF. 
